Blas Frangione Foundation 2018 Young Investigator Research Grant

Sponsor:
NYU Langone Medical Center

Deadline:

October 2, 2017

Summary:

Established in 2009 by Blas Frangione, MD, PhD, Professor Emeritus of Pathology and Psychiatry, the Frangione Foundation supports research in neuroscience. The 2018 Young Investigator Grant aims to fund the next generation of exceptionally creative thinkers with “high-risk/high-reward” ideas, who have the potential to significantly impact our understanding of brain function in normal and diseased states.

Submit a project proposal following the R03 NIH format, along with a biosketch, to Marlena Gordon.

Eligibility:

There is no tenure requirement and Instructors and Research Scientists are also eligible to apply.
Available Funding:

A 2-year award, totaling $100,000 with an anticipated start date of January 1, 2018. Only ONE award will be made.

Link to Full RFP:

Questions about the application should be directed to Dr. Blas Frangione.

Heineken Prizes 2018

Sponsor:

Dr H.P. Heineken Foundation and the Alfred Heineken Fondsen Foundation. The selection of the prizes is entrusted by the Royal Netherlands Academy of Arts and Sciences.

Deadline:

October 15, 2017

Summary:

The Heineken Prizes are intended explicitly for scientists and scholars who are currently active in their field and whose research still holds considerable promise for future innovative discoveries. International juries will select the winners.

Eligibility:

Prizes are available in the following fields:

Available Funding:

$200,000

Link to Full RFP:

http://www.knaw.nl/en/awards/awards/heinekenprizes/heinekenprijs-voor-de-milieuwetenschappen

Parkinson’s Research Program (PRP) – Investigator-Initiated Research Award (IIRA)

Sponsor:

U.S Department of Defense Congressionally Directed Medical Research Programs (CDMRP)

Deadline:

Pre-application: 5 PM EST, August 17, 2017

Application: 11:59 PM EST, August 31, 2017

Summary:

The PRP Investigator-Initiated Research Award (IIRA) mechanism is being offered for the first time in FY17. The PRP Investigator-Initiated Research Award supports highly rigorous, high-impact research projects that have the potential to make an important contribution to Parkinson’s disease research and/or patient care. This award mechanism supports the full spectrum of research from basic science through clinical research that specifically focuses on scientific and clinical Parkinson’s disease issues, which, if successfully addressed, have the potential to make a major impact in understanding, preventing, diagnosing, or treating Parkinson’s disease or enhancing the well-being of individuals experiencing the impact of the disease.
Consistent with the mission of the FY17 PRP to support research to understand, prevent, diagnose, and treat Parkinson’s disease in patients, including Service members and Veterans, investigators are required to address at least one of the following FY17 PRP Focus Areas:
  1. Mechanisms of neuroplasticity in the Parkinson’s disease brain.
  2. Studies to identify gene-environment interactions in Parkinson’s disease cohorts (applications addressing this focus area have an additional submission requirement; please see RFP.
  3. Pathophysiological implications of tau protein in Parkinson’s disease.

Eligibility:

Independent investigators at or above the level of Assistant Professor (or equivalent) are eligible to submit an application as an Initiating or Partnering PI.
Preliminary data to support feasibility are encouraged. Any unpublished, preliminary data provided should originate from the laboratory of the PI or a member(s) of the research team. The preliminary data must support the feasibility of the study.
Partnering PI Option: The Investigator-Initiated Research Award mechanism includes an option for up to three PIs. One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The other PI(s) (maximum of two) will be identified as a Partnering PI(s). Initiating and Partnering PIs each have different submission requirements, please see full RFP.
Available Funding:
  • Single PI:  The anticipated total costs budgeted for the entire period of performance for an FY17 PRP IIRA will not exceed $1M.  The maximum period of performance is three (3) years.
  • Multi PI: The anticipated total costs budgeted for the entire period of performance for an FY17 PRP IIRA will not exceed $2.5M. The maximum period of performance is four (4) years.

Link to Full RFP:

http://cdmrp.army.mil/funding/pa/FY17-PRP-IIRA.pdf

Parkinson’s Research Program (PRP) – Early Investigator Research Award

Sponsor:

U.S Department of Defense Congressionally Directed Medical Research Programs (CDMRP)

Deadline:

Pre-application: 5 PM EST, August 17, 2017

Application: 11:59 PM EST, August 31, 2017

Summary:

The PRP Early Investigator Research Award (EIRA) mechanism is being offered for the first
time in FY17. The PRP Early Investigator Research Award supports Parkinson’s disease-focused research opportunities for individuals in the early stages of their careers, under the guidance of a designated Mentor.
Consistent with the mission of the FY17 PRP to support research to understand, prevent,
diagnose, and treat Parkinson’s disease in patients, including Service members and Veterans,
investigators are required to address at least one of the following FY17 PRP Focus Areas:
  1. Mechanisms of neuroplasticity in the Parkinson’s disease brain.
  2. Studies to identify gene-environment interactions in Parkinson’s disease cohorts (applications addressing this focus area have an additional submission requirement; please see RFP.
  3. Pathophysiological implications of tau protein in Parkinson’s disease.

 

Eligibility:

 The Early Investigator is considered the Principal Investigator (PI) of the application and must exhibit strong potential for, and commitment to, pursuing a career as an investigator at the forefront of Parkinson’s disease research; however, the PI is not required to have previous Parkinson’s disease research experience. Clinical fellows applying to the PRP EIRA mechanism should be specializing in movement disorders.

The investigator must be a postdoctoral or clinical fellow within three years of advanced degree or residency training (or equivalent) as of the application deadline

Applications must include at least one Mentor, appropriate to the proposed research project, who has experience in Parkinson’s disease research and mentoring as demonstrated by a record of active funding, recent publications, and successful mentorship. The selected Mentor(s) should also demonstrate a clear commitment to the development of the PI toward independence as a Parkinson’s disease researcher.

Available Funding:

The anticipated total (direct plus indirect) costs budgeted for the entire period of performance will not exceed $321,000. The maximum period of performance is two (2) years. The PRP’s FY17 appropriation is $16M.

Link to Full RFP:

http://cdmrp.army.mil/funding/pa/FY17-PRP-EIRA.pdf

MSK Lymphoma SPORE 2017-2018 Career Enhancement Program (CEP) Awards

Sponsor:
Hosted at Memorial Sloan Kettering Cancer Center – Funded by the National Institutes of Health

Deadline:

July 28, 2017

Summary:

The aim of this RFA is to identify, train and/or develop talented individuals to become successful translational investigators in the field of lymphoma. The program will support 1 or 2 individuals per year for up to two years per awardee, based on competitive renewal. Awardees will be integrated into the SPORE in order to monitor their progress and ensure successful outcome of their research projects, and will be prepared to obtain independent peer-reviewed funding.

Eligibility:

Investigators at Memorial Sloan Kettering Cancer Center, Rockefeller University, Weill Cornell Medical Center, Columbia University, Mount Sinai Hospital, and NYU, are eligible.
Funds from this program may be used to support junior faculty or established investigators who wish to enhance or refocus their careers on translational research. Eligible candidates will include individuals with the following qualifications:
a) M.D. (or D.O), PhD, or MD/PhD degree. This program is not a training program and does not support pre- or post-doctoral fellows, either pre-clinical or clinical. However, advanced post-doctoral or clinical fellows who provide a letter from an institution stating that the candidate will be joining its faculty within the year are eligible for this program.
b) Commitment to a career path in translational lymphoma research. Candidates must have demonstrated a strong aptitude for and interest in biomedical research, as evidenced by experience in the laboratory or other relevant research.
c) Exceptional clinical candidates that do not currently have an active laboratory program may also apply, provided they have a strong scientific/laboratory background, and are working with a laboratory mentor who can provide them with the necessary guidance and resources to develop a hypothesis that can be tested in the clinical setting
d) Investigators supported by NCI career development awards (K series) may also be eligible for support through this program. Investigators with previous R01 or equivalent level of funding related to lymphoma translational research are not eligible

Anticipated Funding Amount:

The program will support 1 or 2 individuals per year for up to two years per awardee, based on competitive renewal. The maximum award will be $50,000 for one year. Applicants will be funded for a maximum of two years with funding for the second year contingent on documented significant progress during the first year of funding, and peer review evaluations.

PROPOSAL PROCESS:

Proposals cannot be currently funded by an extramural agency or foundation. The budget is limited to $50K/year (direct costs. No indirect costs). Proposals must be submitted to Felicia Reid reidf@mskcc.org by July 24th, 2017.

REQUIRED INFORMATION:

Research proposals must be no longer than 5 pages (excluding budget) and should follow the format for an R01 grant application; the length of the final proposal are limited to 6 pages. The proposals will require the following standard NIH format:
Format: Applications must be in 11-point Arial. Margins must be at least 0.50 inches wide on all sides of each page.
1) Face Page (including Title, Name of Applicant, and Names of Key Collaborators)
2) Abstract (250 words max)
3) Research Plan (5-page limit). Include the following content: Specific Aims, Preliminary Studies, and Research Strategy (a. Significance, b. Innovation, c. Approach)
4) Research environment (1 page)
5) Include up to 6 Literature Citations
6) Human Subjects or Vertebrate Animals. (Please follow the NIH guidelines)
7) NIH Biosketch for all key personnel (5 pages each in NIH-specified format)
8) Budget and Budget Justification. Include a detailed NIH-format Budget for one year totaling $50,000 direct costs. The application must include a detailed budget for the initial year, a summary budget, and a budget justification.
9) The application should include a statement of long-term career goals, letter of support from the mentor with the Mentor’s CV, and 3 letters of recommendation.
REVIEW CRITERIA:
Applications will be reviewed and scored by the CEP Committee, which is composed of a diverse pool of experienced individuals with laboratory and clinical expertise. The CEP Co-Directors will assign two reviewers from the CEP Committee (one primary and one secondary reviewer) for each proposal. The initial selection will be based on the following criteria:
1. Scientific merit of the proposed project
2. Innovation
3. Approach
4. Qualifications of the investigator
5. Qualifications of the mentor
6. Research environment
IRB approval (or waiver) will be required before funding if the study involves human subjects.
SCIENTIFIC REVIEW COMMITTEE:
The CEP Co-Directors will assign two reviewers from the CEP Committee (one primary and one secondary reviewer) for each proposal.
FUNDING CYCLES:
Awards will begin in August 2017
Authors must cite the MSK Lymphoma SPORE (P50 CA192937) in the funding acknowledgements when submitting a manuscript based on research supported, in whole or in part, by this SPORE-Career Enhancement Program.
Written progress and final reports will be required at the end of funding period. Any questions regarding this solicitation should be directed to Felicia Reid reidf@mskcc.org or to the CEP directors; Dr. Riccardo Dalla Favera rd10@cumc.columbia.edu or Dr. Andrew Zelenetz Zelenetz a-zelenetz@ski.mskcc.org.
KEY DATES:
• Applications are due on July 24th, 2017
• Award Announcements by August 18th, 2017
• Award Start Date: August 30th, 2017
SUBMISSION INFORMATION:
Proposals must be submitted electronically to Felicia Reid reidf@mskcc.org. Proposals must be submitted as a compiled PDF document.
ADDITIONAL BUDGET INFORMATION:
Up to $50K direct costs for one year, may be renewable for an additional year based on review
Expenditures allowed
1 Research supplies and animal maintenance.
2 Technical assistance.
3 Publication costs, including reprints.
4 Data analysis.
5 Special fees (pathology, photography, etc.).
6 Stipends for graduate students and postdoctoral fellows.
The following expenditures will not be considered:
1 Secretary or administrative personnel.
2 Office equipment or supplies.
3 Laboratory equipment or computers.
4 Tuition.
5 Foreign travel.
6 Honoraria and travel expenditures.
7 Recruitment.
8 Patient care charges (requires justification if a clinical trial is proposed).
9 Non-medical or personal services to patients

 

MSK Lymphoma SPORE 2017-2018 Developmental Research Program (DRP) Awards

Sponsor:
Hosted at Memorial Sloan Kettering Cancer Center – Funded by the National Institutes of Health

Deadline:

July 28, 2017

Summary:

This RFA is designed to support young investigators as well as established investigators focusing on basic, translational, or clinical research of lymphoma. The primary objective of this DRP Award is to support pilot projects that explore innovative ideas in basic and translational research in lymphoma. Potential topics of interest include, but are not limited to:
• Pathogenesis
• Experimental therapeutics, including mechanism based combinations, and biomarker driven treatment strategies
• Immunology and immunotherapies
• Circulating tumor DNA

Eligibility:

Investigators at Memorial Sloan Kettering Cancer Center, Rockefeller University, Weill Cornell Medical Center, Columbia University, Mount Sinai Hospital, and NYU, are eligible.
Applicants must hold academic rank of Instructor, Assistant Professor, or higher.
Applicants must possess an MD, DO or a PhD degree in a relevant area of research. The pilot projects may be collaborative among scientists within one or more SPOREs, or with scientists outside the SPORE community including the international scientific community. High risk/high payoff pilot projects are especially encouraged. These pilot projects do not need to reach a human endpoint during the project period as do full projects, including the Developmental Research Program. Letters of collaboration (if if applicable)

Proposals cannot be currently funded by an extramural agency or foundation. The budget is limited to $50K/year (direct costs. No indirect costs).

Anticipated Funding Amount:

Each year, 3-4 applications will be funded. The maximum award will be $50,000 for one year. Applicants will be funded for a maximum of two years with funding for the second year contingent on documented significant progress during the first year of funding, and peer review evaluations.

PROPOSAL PROCESS:

Proposals cannot be currently funded by an extramural agency or foundation. The budget is limited to $50K/year (direct costs. No indirect costs). Proposals must be submitted to Felicia Reid reidf@mskcc.org by July 24th, 2017.

REQUIRED INFORMATION:
Research proposals must be no longer than 5 pages (excluding budget) and should follow the format for an R01 grant application; the length of the final proposal are limited to 6 pages. The proposals will require the following standard NIH format:
Format: Applications must be in 11-point Arial. Margins must be at least 0.50 inches wide on all sides of each page.
MSK Lymphoma SPORE
2017-2018 Developmental Research Program (DRP) Awards
1) Face Page (including Title, Name of Applicant, and Names of Key Collaborators)
2) Abstract (250 words max)
3) Research Plan (5-page limit). Include the following content: Specific Aims, Preliminary Studies, and Research Strategy (a. Significance, b. Innovation, c. Approach)
6) Research environment (1 page)
7) Include up to 6 Literature Citations
8) Human Subjects or Vertebrate Animals. (Please follow the NIH guidelines)
9) NIH Biosketch for all key personnel (5 pages each in NIH-specified format)
10) Budget and Budget Justification. Include a detailed NIH-format Budget for one year totaling $50,000 direct costs. The application must include a detailed budget for the initial year, a summary budget, and a budget justification.
REVIEW CRITERIA:
All proposals will be reviewed by the scientific review committee and ad hoc reviewers, according to the following criteria, as relevant:
1. Scientific merit of the proposed project
2. Innovation
3. Approach
4. Qualifications of the investigator
5. Research environment
IRB approval (or waiver) will be required before funding if the study involves human subjects.
SCIENTIFIC REVIEW COMMITTEE:
The DRP Review Committee will include 3 ad hoc members of the SPORE Internal Advisory Board Committee, and 3 ad hoc members of the SPORE External Advisory Board Committee, and 3 additional external reviewers from other lymphoma SPORES
FUNDING CYCLES:
Awards will begin in August 2017
Authors must cite the MSK Lymphoma SPORE (P50 CA192937) in the funding acknowledgements when submitting a manuscript based on research supported, in whole or in part, by this SPORE-Developmental Research Program.
Written progress and final reports will be required at the end of funding period. Any questions regarding this solicitation should be directed to Felicia Reid reidf@mskcc.org or to the DRP directors; Dr. John Leonard jpleonar@med.cornell.edu or Dr. Anas Younes younesa@mskcc.org.
KEY DATES:
• Applications are due on July 24th, 2017
• Award Announcements by August 18th, 2017
• Award Start Date: August 30th, 2017

SUBMISSION INFORMATION:
Proposals must be submitted electronically to Felicia Reid reidf@mskcc.org. Proposals must be submitted as a compiled PDF document.
ADDITIONAL BUDGET INFORMATION: Up to $50K direct costs for one year, may be renewable for an additional year based on review
Expenditures allowed
1 Research supplies and animal maintenance.
2 Technical assistance.
3 Publication costs, including reprints.
4 Data analysis.
5 Special fees (pathology, photography, etc.).
6 Stipends for graduate students and postdoctoral fellows.
The following expenditures will not be considered:
1 Secretary or administrative personnel.
2 Office equipment or supplies.
3 Laboratory equipment or computers.
4 Tuition.
5 Foreign travel.
6 Honoraria and travel expenditures.
7 Recruitment.
8 Patient care charges (requires justification if a clinical trial is proposed).
9 Non-medical or personal services to patients.

SFARI Explorer Awards

Sponsor:

Simons Foundation Autism Research Initiative (SFARI)

Deadline:

Applications are considered on a rolling basis, with a response time as early as 30 days.

Summary:

This award program is designed to enhance our existing support of autism research by providing timely resources to enable focused experiments highly relevant to our mission. A deeper understanding of the mechanisms underlying autism spectrum disorders or potential therapeutic approaches will require investigation at multiple levels, including but not limited to studies focused on gene discovery, molecular mechanisms, circuits, anatomy, and cognition and behavior. We will consider proposals at all of these levels.

Explorer Awards are intended to provide resources to support exploratory experiments that will strengthen hypotheses and lead to the formulation of competitive applications for subsequent larger-scale funding by SFARI or other organizations. Innovative, high-risk/high-impact proposals are encouraged. We especially encourage applications from investigators who are new to the field of autism, but who have expertise that could be brought to bear on this complex disorder.

Eligibility:

All applicants and key collaborators must hold a Ph.D., M.D. or equivalent degree and have a faculty position or the equivalent at a college, university, medical school or other research facility. Applications may be submitted by domestic and foreign nonprofit organizations; public and private institutions, such as colleges, universities, hospitals, laboratories, units of state and local government; and eligible agencies of the federal government. There are no citizenship or country requirements.

Available Funding:

The maximum budget is $70,000, including indirect costs for one (1) year, non-renewable.

Link to Full RFP:

https://sfari.org/funding/grants/explorer-awards-rfa

Integration of Individual Residential Histories into Cancer Research (R21) PA-17-295 and (R01) PA-17-298

Sponsor:

NIH / NCI

Deadline:

Standard R01 dates apply

Standard R21 dates apply

Summary:

The purpose of this Funding Opportunity Announcement (FOA) is to support substantive investigation of the role of individual residential histories in cancer etiology and outcomes, and to encourage the development of complex analytical strategies in support of substantive investigation.

There is a growing recognition of the importance of residential histories – a record of an individual’s places of residence across his or her lifetime — in cancer research, as part of evolving cancer data ecosystem.  Residential history encapsulates a person’s multiple interactions with the social and physical environment that can result in lasting health impact and is an important factor in assessing the effects of exposures on disease onset, as demonstrated in focused studies.  Lifetime residential history records can reveal the variety of potential and actual exposures throughout person’s life including, but not limited to: neighborhood characteristics, physical conditions of housing, tobacco and alcohol consumption, food environments, chemical exposures to contaminants in water, soil, and air, accessibility to healthcare resources, and health disparities.

This FOA is expected to engage scientists from a range of disciplines, including epidemiology, statistics, geospatial science, computer science, demography, decision science, and behavioral science, to effectively integrate individual residential histories into cancer research.

Geospatial expertise is essential for generating new knowledge about the residential context relative to cancer risk, etiology, prevention, treatment, and outcomes. Computer science and informatics are crucial for the development of methodology that would ensure more precise matching of residential information and location (geocoding), improve linkage to automated data sources, and generate reliable lifetime residential histories. Cancer surveillance science, in conjunction with statistical, epidemiological, and medical expertise, is extremely important in answering substantial questions related to the use of lifetime residential histories in the analysis of cancer risk and cancer burden.

In addition, a combination of scientific expertise in demography and behavioral science in addressing the role of lifetime residential histories in the context of cancer can help facilitate more precise assessment of cancer disparities.

Eligibility:

N/A

Available Funding:

R01: Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

R21: The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in a single year. The maximum project period is 2 years.

Link to Full RFP:

R01https://grants.nih.gov/grants/guide/pa-files/PA-17-298.html

R21https://grants.nih.gov/grants/guide/pa-files/PA-17-295.html

Centers for Chemical Innovation – Phase I (CCI) (NSF 17-564)

Sponsor:

National Science Foundation

Deadline:

Preliminary Proposals: September 12, 2017

Full Proposals (by invitation only): March 06, 2018

Summary:

The Centers for Chemical Innovation (CCI) Program supports research centers focused on major, long-term fundamental chemical research challenges. CCIs are agile structures that respond rapidly to emerging opportunities, promote synergy, enhance collaborations, and engage in potentially transformative research. CCIs integrate research, innovation, education, broadening participation, and informal science communication.

The FY 2018 Phase I CCI competition is open to projects in all fields supported by the Division of Chemistry. Successful proposals will have a clear chemistry focus and the potential for transformative impact in chemistry. The Division of Chemistry particularly encourages CCI centers or projects within centers aligned with Data-Driven Discovery Science in Chemistry (D3SC). Such CCI projects would seek new chemical understanding through sharing, mining and repurposing of chemical datasets and through the use of state-of-the-art data analysis techniques. Additional context for D3SC and links to related documents can be found at NSF 17-036.

The research activities may build on pre-existing efforts, but new, collaborative results attributed to the CCI award are expected. The Phase I award will also develop broader impact activities in the four required areas (see below), including piloting and developing center-scale activities commensurate with a Phase II CCI. Center development includes the development of a strategic plan covering all aspects of a CCI (see full RFP).

CCIs are expected to integrate their research with activities that broaden the impact of their research. A Phase I team might pilot activities in these areas:

  • Innovation – translation or transfer of basic research results into economic or societal benefit. This element includes intellectual property protection and a proactive plan to either engage industry in technology transfer or to commercialize technology in other ways.
  • Higher Education and Professional Development – education and professional development for undergraduate and graduate students supported by the grant, including co-mentorship or other collaborative training and continued professional development and mentoring for postdoctoral research associates. This may also include education in various aspects of innovation (intellectual property, entrepreneurship, etc.) and other higher education activities (i.e., new course materials or curricula).
  • Broadening the participation of underrepresented groups – CCI goals for increasing engagement by underrepresented groups, plans for reaching those goals, and an evaluation strategy.
  • Informal science communication – plans for communicating the CCI research to public audiences and possible ways to evaluate the impact of these outreach efforts.

Eligibility:

Who May Serve as PI:

  • While these proposals will reflect the research of many investigators, only the name of the Principal Investigator (PI) should appear on the cover sheet. All other investigators are considered Faculty Associates (non-coPI senior personnel). An investigator may participate (as PI or Faculty Associate) in only one CCI preliminary proposal and one CCI full proposal (Phase I or Phase II) submitted to this competition. The PI must be affiliated with an eligible submitting organization.

Limit on Number of Proposals per PI or Co-PI: 1

  • An investigator may participate (as PI or Faculty Associate) in only one preliminary proposal and one full proposal (Phase I or Phase II) submitted in response to this solicitation. The PI must be affiliated with an eligible submitting organization.

The team of investigators for a Phase I proposal must include at least four senior researchers with complementary expertise. While there is no upper limit on the number of Phase I investigators, proposers are cautioned to avoid teams that are too large to collaborate effectively. The available resources should also be carefully considered in assembling the team. CCIs may partner with researchers from industry, national laboratories and international organizations. See detailed guidance below for non-U.S. or non-academic researchers.

Available Funding:

NSF anticipates making three new Phase I awards (up to $1,800,000 for 3 years) as standard or continuing grants.

Link to Full RFP:

https://www.nsf.gov/pubs/2017/nsf17564/nsf17564.htm?WT.mc_id=USNSF_25&WT.mc_ev=click#elig

ONR Young Investigator Program

Sponsor:

Office of Naval Research

Deadline:

September 15, 2017

Summary:

The Office of Naval Research (ONR) is interested in receiving proposals for its Young Investigator Program (YIP). ONR’s Young Investigator Program (YIP) seeks to identify and support academic scientists and engineers who are in their first or second full-time tenure-track or tenure-trackequivalent academic appointment, have begun their first appointment on or after 31 December 2012, and who show exceptional promise for doing creative research. The objectives of this program are to attract outstanding faculty members of Institutions of Higher Education (hereafter also called “universities”) to the Department of the Navy’s Science and Technology (S&T) research program, to support their research, and to encourage their teaching and research careers.

Proposals addressing research areas (as described in the ONR Science and Technology Department section of ONR’s website at www.onr.navy.mil) which are of interest to ONR program officers will be considered. Contact information for each division (a subgroup of an S&T Department) is also listed within the S&T section of the website.

Eligibility:

The Principal Investigator of a proposal must be a U.S. citizen, national, or permanent resident (on the date proposals are due), holding a first or second full-time tenure-track or tenure-track-equivalentfaculty position at that university, and has begun her/his first full-time appointment on or after 31 December 2012.

Available Funding:

Applicants may request up to $170,000 per year for three (3) years. (Additional funds for capital equipment which enhances the Young Investigator’s proposed research may be requested.)

Link to Full RFP:

https://www.grants.gov/custom/viewOppDetails.jsp?oppId=294449